Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001654954-22-006980
Filing Date
2022-05-16
Accepted
2022-05-16 16:33:18
Documents
51
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tenx_10q.htm   iXBRL 10-Q 523540
2 CERTIFICATION tenx_ex311.htm EX-31.1 12515
3 CERTIFICATION tenx_ex312.htm EX-31.2 10731
4 CERTIFICATION tenx_ex321.htm EX-32.1 5992
5 CERTIFICATION tenx_ex322.htm EX-32.2 6262
  Complete submission text file 0001654954-22-006980.txt   2811168

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tenx-20220331.xsd EX-101.SCH 35889
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tenx-20220331_lab.xml EX-101.LAB 201558
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tenx-20220331_cal.xml EX-101.CAL 32089
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tenx-20220331_pre.xml EX-101.PRE 157625
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tenx-20220331_def.xml EX-101.DEF 72853
45 EXTRACTED XBRL INSTANCE DOCUMENT tenx_10q_htm.xml XML 304766
Mailing Address ONE COPLEY PARKWAY SUITE 490 MORRISVILLE NC 27560
Business Address ONE COPLEY PARKWAY SUITE 490 MORRISVILLE NC 27560 919-806-4414
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34600 | Film No.: 22929890
SIC: 2834 Pharmaceutical Preparations